sequence under fasting conditions and at least 28 days washout period between the doses.,A randomized&#44

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Drospirenone + Ethinyl Estradiol 3.00/0.03 mg Tablet relative to Yasmin(R) (Drospirenone + Ethinyl Estradiol 3.00/0.03 mg Tablet) in healthy Thai female volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Entecavir 1 mg tablets relative to Baraclude® 1 mg tablets in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single-dose, two-way crossover design with two-period, two-treatment and two-sequence of Donepezil 10 mg Orodispersible Tablets relative to Aricept® Evess orodispersible tablets 10 mg in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single-dose, two-way crossover design with two-period, two-treatment and two-sequence of Dutasteride 0.5 mg soft capsules relative to Avodart® in healthy Thai male volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Entecavir 0.5 mg tablets relative to Baraclude® 0.5 mg tablets in healthy Thai volunteers under fasting condition